Strategy & Trends with Forecasts by Assay Type, by Place, by Product, and by Country. Situation Analysis with Executive & Consultant Guides. 2025 to 2029"
Published November 2024 – 367 pages
The Clinical Laboratory rose to the COVID challenge, but the end of the pandemic has created a new approach to diagnostics. Point of Care and Self Testing are threatening long term demand for clinical lab services but Molecular Diagnostics is driving runaway growth. Understand the opportunities and the threats in this comprehensive report.
The fundamentals are still here. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations.
The report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help sharpen your pricing. Forecast demand for new testing regimes or technologies. Make research investment decisions.
The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.
All report data is available in Excel format on request.
Make investment decisions and valuations with confidence using the latest data.
Our reports are sold on a 12 Month Subscription basis. Buying a report entitles you to the original current report plus an additional 1 to 3 follow on updated reports.
1 Market Guides …………………………………………………………………………………………………… 17
1.1 Strategic Situation Analysis …………………………………………………………………………………. 18
1.2 Guide for Executives, Marketing, Sales and Business Development Staff ………………. 21
1.3 Guide for Management Consultants and Investment Advisors …………………………….. 22
2 Introduction and Market Definition …………………………………………………………………….. 23
2.1 The New Demand for Clinical Testing ………………………………………………………………….. 24
2.2 Defining the Opportunity ……………………………………………………………………………………. 26
2.2.1 Revenue Market Size ………………………………………………………………………………………. 26
2.3 Methodology …………………………………………………………………………………………………….. 28
2.3.1 Methodology …………………………………………………………………………………………………. 28
2.3.2 Sources ………………………………………………………………………………………………………….. 28
2.3.3 Authors ………………………………………………………………………………………………………….. 28
2.4 Perspective: Healthcare and the IVD Industry …………………………………………………….. 30
2.4.1 Global Healthcare Spending ………………………………………………………………………….. 30
2.4.2 Spending on Diagnostics ………………………………………………………………………………… 32
2.4.3 Important Role of Insurance for Diagnostics …………………………………………………….. 33
3 Overview of a Dynamic Market ………………………………………………………………………….. 34
3.1 Players in a Dynamic Market ………………………………………………………………………………. 35
3.1.1 Academic Research Lab ……………………………………………………………………………….. 36
3.1.2 Diagnostic Test Developer ………………………………………………………………………………. 36
3.1.3 Instrumentation Supplier …………………………………………………………………………………. 37
3.1.4 Chemical/Reagent Supplier ……………………………………………………………………………. 37
3.1.5 Pathology Supplier …………………………………………………………………………………………. 37
3.1.6 Independent Clinical Laboratory ……………………………………………………………………. 37
3.1.7 Public National/regional Laboratory ……………………………………………………………….. 38
3.1.8 Hospital Laboratory ………………………………………………………………………………………… 38
3.1.9 Physicians Office Lab (POLS) …………………………………………………………………………… 39
3.1.10 Audit Body ………………………………………………………………………………………………….. 39
3.1.11 Certification Body ……………………………………………………………………………………….. 39
3.2 Segmentation – Different Approaches ……………………………………………………………….. 41
3.2.1 Traditional Market Segmentation…………………………………………………………………….. 41
3.2.2 Laboratory Focus and Segmentation ………………………………………………………………. 43
3.3 Structure of Clinical Testing Industry ……………………………………………………………………. 45
3.3.1 The Hospital Lab – Share of the Pie ………………………………………………………………….. 45
3.3.2 Key Role for Economies of Scale ……………………………………………………………………… 45
3.3.3 Physician Office Lab’s are Still Here …………………………………………………………………. 47
3.3.4 Physician’s and POCT – Reviving Patient Service in China ………………………………… 48
3.4 National and Regional Diversity ………………………………………………………………………….. 49
4 Trends Driving a Changing Market ……………………………………………………………………… 51
4.1 Growth Is Pushed from Many Sides ……………………………………………………………………… 52
4.1.1 Demographic Impacts on Consumption …………………………………………………………. 53
4.1.2 COVID Related Impacts …………………………………………………………………………………. 55
4.1.3 Point of Care Testing Makes a Difference ………………………………………………………… 55
4.1.4 Alternative Medicine Effect …………………………………………………………………………….. 56
4.1.5 Esoterics …………………………………………………………………………………………………………. 57
4.1.6 A New Laboratory Discipline …………………………………………………………………………… 57
4.2 Factors at Work to Shrink the Market …………………………………………………………………… 58
4.2.1 Where are Costs Going? ………………………………………………………………………………… 59
4.2.2 Population Effects ………………………………………………………………………………………….. 59
4.2.3 Management Practices ………………………………………………………………………………….. 59
4.2.4 Wellness …………………………………………………………………………………………………………. 59
4.2.5 Cannabilization ……………………………………………………………………………………………… 59
4.2.6 Point of Care ………………………………………………………………………………………………….. 60
4.3 Automation and Laboratory Trends ……………………………………………………………………. 61
4.3.1 Traditional Automation and Centralization ………………………………………………………. 61
4.3.2 The New Automation, Decentralization and Point Of Care ………………………………. 61
4.3.3 Instruments Key to Market Share ……………………………………………………………………… 63
4.3.4 Bioinformatics Plays a Role ……………………………………………………………………………… 63
4.3.5 PCR Takes Command …………………………………………………………………………………….. 63
4.3.6 Next Generation Sequencing Fuels a Revolution ……………………………………………… 65
4.3.7 NGS Impact on Pricing ……………………………………………………………………………………. 66
4.3.8 Whole Genome Sequencing, A Brave New World …………………………………………… 66
4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment …………………………………… 66
4.3.10 Shifting Role of Diagnostics ………………………………………………………………………….. 67
5 Clinical Laboratory Services Recent Developments …………………………………………….. 69
5.1 Recent Developments – Importance and How to Use This Section ………………………. 70
5.1.1 Importance of These Developments ……………………………………………………………….. 70
5.1.2 How to Use This Section …………………………………………………………………………………… 70
5.2 Siemens Healthineers Reach New Level of Automation ………………………………………. 70
5.3 Clinical Laboratory Prostate Cancer Screening Concerns …………………………………… 72
5.4 Clinical Labs Prepare for AI ………………………………………………………………………………… 75
5.5 Self-Testing and AI to Change Clinical Labs ………………………………………………………… 78
5.6 Atalan Sees Potential in Hospital Outreach Business ……………………………………………. 80
5.7 Challenge Bringing Routine Testing to Point of Care ……………………………………………. 83
5.8 Natera Cites Test Volume Growth, Rosy Reimbursement ……………………………………… 88
5.9 Patients Becoming Stakeholders in Infectious Disease Testing ………………………………. 91
5.10 MedGenome Acquires Prognosis Laboratories ………………………………………………….. 104
5.11 Brooks Automation acquires Aim Lab ……………………………………………………………….. 104
5.12 Avalon GloboCare Announces Strategic Investment in Laboratory Services MSO . 105
5.13 Mayo Clinic Laboratories and Helix to provide Biopharma Services ……………………. 106
5.14 CompuGroup Medical acquires Medicus Laboratory Information Systems …………. 107
5.15 Quest Diagnostics acquires Summa Health outreach lab ………………………………….. 108
5.16 Q2 Solutions Launches Self-Collection Safety Lab Panel ……………………………………… 108
5.17 Bionano Genomics Announces Launch of Bionano Laboratories ……………………….. 109
5.18 Labcorp to Spin Off Clinical Development Business …………………………………………… 110
5.19 Value-Based Care Growing More Profitable for Labs …………………………………………. 112
5.20 Lucid Diagnostics Reports Revenue Growth ………………………………………………………. 115
5.21 NGS Cancer Testing Decision Appeases Industry ………………………………………………. 116
5.22 Clinical Labs Make Strong Showing in 2021 ……………………………………………………….. 120
5.23 Seegene to Enter Syndromic MDx Space ………………………………………………………….. 124
5.24 EKF Diagnostics Acquires Advanced Diagnostic Laboratory ………………………………. 128
5.25 Molecular Health, EDGC Ink Liquid Biopsy Partnership ……………………………………….. 129
5.26 ProPhase Labs Acquires Nebula Genomics for $14.6M ………………………………………. 129
5.27 Karius Cell-Free DNA Method to Detect Infection Validated ……………………………… 130
5.28 EDGC Enters Liquid Biopsy Space With Cf DNA ………………………………………………….. 133
5.29 TruDiagnostic Receives CLIA Certification for Kentucky Laboratory ……………………. 136
5.30 Enzo Biochem Q2 Revenues Up 62 Percent ……………………………………………………….. 136
5.31 Thermo Fisher Gets CE Mark for High-Throughput COVID-19 Assay ……………………… 137
5.32 FDA Issues Alert – False Negatives due to SARS-CoV-2 Mutations ………………………… 138
5.33 Will Labs Use Expanded Molecular Testing Capacities Post-COVID-19? ………………. 140
5.34 Chinese Infectious Dx Firm Vision Medicals Completes Series B Financing …………… 144
5.35 Cooperative Aims to Expand Clinical, Commercial NGS Access………………………… 144
6 Profiles of Key Companies ………………………………………………………………………………… 148
6.1 Acibadem Labmed Laboratory ……………………………………………………………………….. 149
6.2 ACM Medical Laboratory …………………………………………………………………………………. 151
6.3 Adicon Clinical Laboratories …………………………………………………………………………….. 152
6.4 American Bio-Clinical Laboratories, Int’l …………………………………………………………….. 153
6.5 ARUP Laboratories ……………………………………………………………………………………………. 154
6.6 Ascend Clinical ……………………………………………………………………………………………….. 156
6.7 Assurance Scientific Laboratories ……………………………………………………………………… 157
6.8 Bio-Reference Laboratories ………………………………………………………………………………. 158
6.9 Bioscientia Institut für Medizinische Diagnostik GmbH ………………………………………… 159
6.10 BP Healthcare Group ……………………………………………………………………………………….. 160
6.11 Clinical Reference Laboratory ………………………………………………………………………….. 161
6.12 Clongen Laboratories ………………………………………………………………………………………. 162
6.13 CompuNet Clinical Laboratories ………………………………………………………………………. 163
6.14 Diagnósticos da América …………………………………………………………………………………. 164
6.15 DIAN Diagnostics Co., Ltd. ………………………………………………………………………………… 165
6.16 Enzo Biochem ………………………………………………………………………………………………….. 167
6.17 Eone Laboratories ……………………………………………………………………………………………. 168
6.18 Eurofins Scientific ……………………………………………………………………………………………… 169
6.19 Exagen Diagnostics ………………………………………………………………………………………….. 171
6.20 Genzyme Corporation ……………………………………………………………………………………… 172
6.21 Gribbles Pathology …………………………………………………………………………………………… 173
6.22 Guangzhou Kingmed Diagnostics Group Co., Ltd. …………………………………………….. 174
6.23 Integrated Regional Laboratories ……………………………………………………………………… 175
6.24 KDL Group ……………………………………………………………………………………………………….. 176
6.25 Laboratory Corporation of America………………………………………………………………….. 177
6.26 Lifelabs ……………………………………………………………………………………………………………. 178
6.27 Mayo Clinic Laboratories ………………………………………………………………………………….. 179
6.28 Mid America Clinical Laboratories ……………………………………………………………………. 180
6.29 MNG Labs ……………………………………………………………………………………………………….. 181
6.30 Myriad Genetics/Myriad RBM …………………………………………………………………………… 182
6.31 NeoGenomics …………………………………………………………………………………………………. 183
6.32 OncoDNA ……………………………………………………………………………………………………….. 184
6.33 Pathology, Inc. ………………………………………………………………………………………………… 185
6.34 ProPhase Labs …………………………………………………………………………………………………. 186
6.35 Psychemedics Corporation ………………………………………………………………………………. 187
6.36 Quest Diagnostics ……………………………………………………………………………………………. 188
6.37 RDL Reference Laboratory ……………………………………………………………………………….. 189
6.38 Sonic Healthcare ……………………………………………………………………………………………… 190
6.39 Sophia Genetics ………………………………………………………………………………………………. 191
6.40 Spectra Laboratories ……………………………………………………………………………………….. 192
6.41 Synlab ……………………………………………………………………………………………………………… 193
6.42 Sysmex Inostics…………………………………………………………………………………………………. 195
6.43 Unilabs …………………………………………………………………………………………………………….. 196
6.44 Werfen …………………………………………………………………………………………………………….. 197
7 The Global Market for Clinical Laboratory Testing ……………………………………………… 199
7.1 Global Market Overview by Country ………………………………………………………………… 200
7.1.1 Table – Global Market by Country …………………………………………………………………. 200
7.1.2 Chart – Global Market by Country …………………………………………………………………. 201
7.2 Global Market by Assay Type – Overview ………………………………………………………….. 202
7.2.1 Table – Global Market by Assay Type …………………………………………………………….. 202
7.2.2 Chart – Global Market by Assay Type – Base/Final Year Comparison………………. 203
7.2.3 Chart – Global Market by Assay Type – Base Year ………………………………………….. 204
7.2.4 Chart – Global Market by Assay Type – End Year …………………………………………… 205
7.2.5 Chart – Global Market by Assay Type – Share by Year ……………………………………. 206
7.2.6 Chart – Global Market by Assay Type – Segments Growth ……………………………… 207
7.3 Global Market by Place – Overview ………………………………………………………………….. 208
7.3.1 Table – Global Market by Place …………………………………………………………………….. 208
7.3.2 Chart – Global Market by Place – Base/Final Year Comparison ……………………… 209
7.3.3 Chart – Global Market by Place – Base Year………………………………………………….. 210
7.3.4 Chart – Global Market by Place – End Year …………………………………………………… 211
7.3.5 Chart – Global Market by Place – Share by Year ……………………………………………. 212
7.3.6 Chart – Global Market by Place – Segments Growth ……………………………………… 213
7.4 Global Market by Product – Overview ………………………………………………………………. 214
7.4.1 Table – Global Market by Product …………………………………………………………………. 214
7.4.2 Chart – Global Market by Product – Base/Final Year Comparison …………………… 215
7.4.3 Chart – Global Market by Product – Base Year ………………………………………………. 216
7.4.4 Chart – Global Market by Product – End Year ……………………………………………….. 217
7.4.5 Chart – Global Market by Product – Share by Year ………………………………………… 218
7.4.6 Chart – Global Market by Product – Segments Growth ………………………………….. 219
8 Global Clinical Laboratory Diagnostic Markets – By Assay Type …………………………. 220
8.1 Chemistry ………………………………………………………………………………………………………… 221
8.1.1 Table Chemistry – by Country ……………………………………………………………………….. 221
8.1.2 Chart – Chemistry Growth ……………………………………………………………………………… 222
8.2 Microbiology ……………………………………………………………………………………………………. 223
8.2.1 Table Microbiology – by Country …………………………………………………………………… 223
8.2.2 Chart – Microbiology Growth ………………………………………………………………………… 224
8.3 Hematology …………………………………………………………………………………………………….. 225
8.3.1 Table Hematology – by Country ……………………………………………………………………. 225
8.3.2 Chart – Hematology Growth …………………………………………………………………………. 226
8.4 Anatomic Pathology ………………………………………………………………………………………… 227
8.4.1 Table Anatomic Pathology – by Country ……………………………………………………….. 227
8.4.2 Chart – Anatomic Pathology Growth …………………………………………………………….. 228
8.5 Molecular Diagnostics ……………………………………………………………………………………… 229
8.5.1 Table Molecular Diagnostics – by Country ……………………………………………………… 229
8.5.2 Chart – Molecular Diagnostics Growth …………………………………………………………… 230
8.6 Esoteric ……………………………………………………………………………………………………………. 231
8.6.1 Table Esoteric – by Country …………………………………………………………………………… 231
8.6.2 Chart – Esoteric Growth…………………………………………………………………………………. 232
9 Global Clinical Laboratory Diagnostic Markets – By Place …………………………………. 233
9.1 In Patient Hospital …………………………………………………………………………………………….. 234
9.1.1 Table In Patient Hospital – by Country ……………………………………………………………. 234
9.1.2 Chart – In Patient Hospital Growth …………………………………………………………………. 235
9.2 Out Patient Hospital …………………………………………………………………………………………. 236
9.2.1 Table Out Patient Hospital – by Country ………………………………………………………… 236
9.2.2 Chart – Out Patient Hospital Growth ………………………………………………………………. 237
9.3 Independent Laboratory ………………………………………………………………………………….. 238
9.3.1 Table Independent Laboratory – by Country …………………………………………………. 238
9.3.2 Chart – Independent Laboratory Growth ………………………………………………………. 239
9.4 Physicians Office Laboratory …………………………………………………………………………….. 240
9.4.1 Table Physicians Office Laboratory – by Country ……………………………………………. 240
9.4.2 Chart – Physicians Office Laboratory Growth …………………………………………………. 241
9.5 Other Laboratory ……………………………………………………………………………………………… 242
9.5.1 Table Other Laboratory – by Country …………………………………………………………….. 242
9.5.2 Chart – Other Laboratory Growth ………………………………………………………………….. 243
10 Global Clinical Laboratory Diagnostic Markets – By Product ………………………….. 244
10.1 Instruments ………………………………………………………………………………………………………. 245
10.1.1 Table Instruments – by Country ………………………………………………………………….. 245
10.1.2 Chart – Instruments Growth ………………………………………………………………………… 246
10.2 Reagents …………………………………………………………………………………………………………. 247
10.2.1 Table Reagents – by Country …………………………………………………………………….. 247
10.2.2 Chart – Reagents Growth …………………………………………………………………………… 248
10.3 Labour …………………………………………………………………………………………………………….. 249
10.3.1 Table Labour – by Country ………………………………………………………………………… 249
10.3.2 Chart – Labour Growth ………………………………………………………………………………. 250
10.4 Overhead ……………………………………………………………………………………………………….. 251
10.4.1 Table Overhead – by Country ……………………………………………………………………. 251
10.4.2 Chart – Overhead Growth …………………………………………………………………………. 252
10.5 Other Product ………………………………………………………………………………………………….. 253
10.5.1 Table Other Product – by Country ……………………………………………………………… 253
10.5.2 Chart – Other Product Growth ……………………………………………………………………. 254
11 The Future of the Clinical Laboratory ……………………………………………………………. 255
12 Appendices ………………………………………………………………………………………………… 256
12.1 United States Medicare System: Clinical Laboratory Fees Schedule …………………… 257
12.2 The Most Used IVD Assays …………………………………………………………………………………. 356
12.3 The Highest Grossing Assays ……………………………………………………………………………… 361
Profiles of Key Players
6.1 Acibadem Labmed Laboratory
6.2 ACM Medical Laboratory
6.3 Adicon Clinical Laboratories
6.4 American Bio-Clinical Laboratories, Int’l
6.5 ARUP Laboratories
6.6 Ascend Clinical
6.7 Assurance Scientific Laboratories
6.8 Bio-Reference Laboratories
6.9 Bioscientia Institut für Medizinische Diagnostik GmbH
6.10 BP Healthcare Group
6.11 Clinical Reference Laboratory
6.12 Clongen Laboratories
6.13 CompuNet Clinical Laboratories
6.14 Diagnósticos da América
6.15 DIAN Diagnostics Co., Ltd.
6.16 Enzo Biochem
6.17 Eone Laboratories
6.18 Eurofins Scientific
6.19 Exagen Diagnostics
6.20 Genzyme Corporation
6.21 Gribbles Pathology
6.22 Guangzhou Kingmed Diagnostics Group Co., Ltd.
6.23 Integrated Regional Laboratories
6.24 KDL Group
6.25 Laboratory Corporation of America
6.26 Lifelabs
6.27 Mayo Clinic Laboratories
6.28 Mid America Clinical Laboratories
6.29 MNG Labs
6.30 Myriad Genetics/Myriad RBM
6.31 NeoGenomics
6.32 OncoDNA
6.33 Pathology, Inc.
6.34 ProPhase Labs
6.35 Psychemedics Corporation
6.36 Quest Diagnostics
6.37 RDL Reference Laboratory
6.38 Sonic Healthcare
6.39 Sophia Genetics
6.40 Spectra Laboratories
6.41 Synlab
6.42 Sysmex Inostics
6.43 Unilabs
6.44 Werfen
Table of Tables
Table 1 Market Players by Type ……………………………………………………………………………………….. 36
Table 2 Clinical Laboratory Departments and Segments …………………………………………………… 42
Table 3 Laboratory Management Focus – Different Approaches ………………………………………. 43
Table 4 Key Segmentation Variables Going Forward…………………………………………………………. 44
Table 5 Factors Affecting Local Clinical Testing Demand ………………………………………………….. 49
Table 6 Seven Factors Driving Growth ………………………………………………………………………………. 52
Table 7 Alternative Medicine Segments ……………………………………………………………………………. 56
Table 8 Six Factors Limiting Growth …………………………………………………………………………………… 58
Table 9 Seven Key Diagnostic Laboratory Technology Trends ……………………………………………. 61
Table 10 – Global Market by Region ……………………………………………………………………………….. 200
Table 11 Global Market by Assay Type ……………………………………………………………………………. 202
Table 12 Global Market by Place ……………………………………………………………………………………. 208
Table 13 Global Market by Product ………………………………………………………………………………… 214
Table 14 Chemistry by Country ………………………………………………………………………………………. 221
Table 15 Microbiology by Country …………………………………………………………………………………. 223
Table 16 Hematology by Country …………………………………………………………………………………… 225
Table 17 Anatomic Pathology by Country ………………………………………………………………………. 227
Table 18 Molecular Diagnostics by Country …………………………………………………………………….. 229
Table 19 Esoteric by Country ………………………………………………………………………………………….. 231
Table 20 In Patient Hospital by Country …………………………………………………………………………… 234
Table 21 Out Patient Hospital by Country ………………………………………………………………………. 236
Table 22 Independent Laboratory by Country ………………………………………………………………… 238
Table 23 Physicians Office Laboratory by Country …………………………………………………………… 240
Table 24 Other Laboratory by Country ……………………………………………………………………………. 242
Table 25 Instruments by Country …………………………………………………………………………………….. 245
Table 26 Reagents by Country ………………………………………………………………………………………. 247
Table 27 Labour by Country …………………………………………………………………………………………… 249
Table 28 Overhead by Country ………………………………………………………………………………………. 251
Table 29 Other Product by Country ………………………………………………………………………………… 253
Table 30 Clinical Lab Fee Schedule ……………………………………………………………………………….. 257
Table 31 The Most Common Assays ……………………………………………………………………………….. 356
Table 32 Largest Revenue Assays ……………………………………………………………………………………. 361
Table of Figures
Figure 1 Global Healthcare Spending ………………………………………………………………………………. 31
Figure 2 The Road to Diagnostics ……………………………………………………………………………………… 35
Figure 3 The Changing Age of The World’s Population ………………………………………………………. 53
Figure 4 Health Care Consumption by Age ………………………………………………………………………. 54
Figure 5 Cancer Incidence – Age at Diagnosis …………………………………………………………………. 55
Figure 6 Centralized vs. Decentralized Laboratory Service ………………………………………………… 62
Figure 7 A Highly Multiplexed Syndromic Testing Unit …………………………………………………………. 62
Figure 8 The Real Cost to Sequence the Human Genome…………………………………………………. 65
Figure 9 The Codevelopment Process ………………………………………………………………………………. 67
Figure 10 Comparing MDx Diagnostic and Traditional Testing ……………………………………………. 68
Figure 11 Global Market Pareto Chart ……………………………………………………………………………. 201
Figure 12 Global Market by Assay Type – Base vs. Final …………………………………………………….. 203
Figure 13 Global Market by Assay Type Base Year …………………………………………………………… 204
Figure 14 Global Market by Assay Type End Year ……………………………………………………………. 205
Figure 15 Assay Type Share by Year ………………………………………………………………………………… 206
Figure 16 Assay Type Segments Growth ………………………………………………………………………….. 207
Figure 17 Global Market by Place – Base vs. Final…………………………………………………………….. 209
Figure 18 Global Market by Place Base Year …………………………………………………………………… 210
Figure 19 Global Market by Place End Year ……………………………………………………………………. 211
Figure 20 Place Share by Year ………………………………………………………………………………………… 212
Figure 21 Place Segments Growth ………………………………………………………………………………….. 213
Figure 22 Global Market by Product – Base vs. Final …………………………………………………………. 215
Figure 23 Global Market by Product Base Year ……………………………………………………………….. 216
Figure 24 Global Market by Product End Year …………………………………………………………………. 217
Figure 25 Product Share by Year …………………………………………………………………………………….. 218
Figure 26 Product Segments Growth ………………………………………………………………………………. 219
Figure 27 Chemistry Growth ……………………………………………………………………………………………. 222
Figure 28 Microbiology Growth ………………………………………………………………………………………. 224
Figure 29 Hematology Growth ……………………………………………………………………………………….. 226
Figure 30 Anatomic Pathology Growth …………………………………………………………………………… 228
Figure 31 Molecular Diagnostics Growth …………………………………………………………………………. 230
Figure 32 Esoteric Growth ………………………………………………………………………………………………. 232
Figure 33 In Patient Hospital Growth ……………………………………………………………………………….. 235
Figure 34 Out Patient Hospital Growth …………………………………………………………………………….. 237
Figure 35 Independent Laboratory Growth …………………………………………………………………….. 239
Figure 36 Physicians Office Laboratory Growth ……………………………………………………………….. 241
Figure 37 Other Laboratory Growth ………………………………………………………………………………… 243
Figure 38 Instruments Growth …………………………………………………………………………………………. 246
Figure 39 Reagents Growth ……………………………………………………………………………………………. 248
Figure 40 Labour Growth ………………………………………………………………………………………………… 250
Figure 41 Overhead Growth …………………………………………………………………………………………… 252
Figure 42 Other Product Growth …………………………………………………………………………………….. 254
Since 2001 Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. We publish market research reports that address scientific industries with an emphasis on Biotechnology, Medical Imaging, Pharmaceutical and Clinical Diagnostic markets. We consider ourselves experts in these areas. This contrasts with the many research mills that produce canned reports on the Handbag market one day and the X-ray market the next.
We approach market research differently than other companies. At any one time we have a limited number of reports and we update them two to four times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area.
Our service goes beyond research reports. We often provide, at no extra cost, information that will help you apply our numbers to your unique situation. We’ve been doing this for years. Buying more than one report at a time can provide significant savings and upgraded licensing.
Our reports are sold on a 12 Month Subscription basis. Buying a report entitles you to the original current report plus an additional 1 to 3 follow on updated reports. At least one of these will include numbers and forecasts with an additional year. These reports are sent to you directly as they are released. This allows you to stay current on the situation and outlook in your area of interest. Your initial subscription can be renewed at a significantly discounted rate so that you can continue to keep on top of market developments. This program allows you to follow very specific market areas in detail in an ongoing and cost-effective way.
